Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma

NCT05448677 2025-04-20

ABE-LIVER

Phase 2 Terminated

3 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04629339 2025-03-13

Study of INCB086550 in Select Solid Tumors

Phase 2 Terminated

16 enrolled 17 charts

DermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis

NCT05137899 2025-03-11

ADVANCE HCC

Phase 2 Terminated

1 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT01205828 2025-02-12

ABT-888 and Temozolomide for Liver Cancer

Phase 2 Terminated

16 enrolled 11 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05776875 2025-01-15

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Phase 2 Terminated

3 enrolled 6 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05653427 2025-01-13

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Phase 2 Terminated

18 enrolled 20 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03145558 2024-11-22

TATE

Phase 2 Terminated

6 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT01101906 2024-11-20

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Phase 2 Terminated

23 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00687596 2024-09-19

Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

Phase 2 Terminated

52 enrolled 20 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04541173 2024-06-05

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Phase 2 Terminated

6 enrolled 17 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03591965 2023-07-10

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Phase 2 Terminated

73 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05249569 2023-05-03

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

Phase 2 Terminated

1 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03582618 2023-01-10

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

Phase 2 Terminated

12 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01433016 2022-12-20

OBT for HCC

Phase 2 Terminated

20 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT01381211 2022-12-15

TRACE

Phase 2 Terminated

72 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03781960 2022-12-14

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

Phase 2 Terminated

7 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT02415036 2022-10-17

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Phase 2 Terminated

17 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT00746590 2022-07-21

Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

Phase 2 Terminated

1 enrolled 5 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT04653389 2022-01-11

Perioperative Therapy for Hepatocellular Carcinoma

Phase 2 Terminated

10 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT04476329 2021-12-30

ReDos HCC

Phase 2 Terminated

7 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT01032850 2021-06-02

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Phase 2 Terminated

15 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT03608878 2021-05-06

Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype

Phase 2 Terminated

5 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT03303469 2021-02-21

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

Phase 2 Terminated

3 enrolled 4 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03008512 2021-02-04

A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib

Phase 2 Terminated

5 enrolled

Gastrointestinal

Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms by Site

NCT02524119 2021-02-01

LEE001

Phase 2 Terminated

5 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03219372 2021-01-22

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

Phase 2 Terminated

1 enrolled 5 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03433703 2019-12-06

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

Phase 2 Terminated

8 enrolled 8 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03318562 2019-07-18

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Phase 2 Terminated

3 enrolled

BreastGastrointestinal

Carcinoma, Hepatocellular, Triple Negative Breast Neoplasms

NCT02950025 2019-04-03

Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

Phase 2 Terminated

5 enrolled 12 charts

Gastrointestinal

Carcinoma, Hepatocellular, Pancreatic Neoplasms

NCT02267213 2019-02-26

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Phase 2 Terminated

29 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00832637 2018-06-29

Gem-ox

Phase 2 Terminated

33 enrolled 9 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT00459108 2018-04-19

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Phase 2 Terminated

25 enrolled 7 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00903396 2017-11-24

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

Phase 2 Terminated

7 enrolled 1 chart

Gastrointestinal

Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Nausea, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Vomiting, Colorectal Neoplasms

NCT02549755 2017-11-22

11C-acetate for Treatment Response After Radiotherapy for HCC

Phase 2 Terminated

1 enrolled 3 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT00003530 2017-11-21

Antineoplaston Therapy in Treating Patients With Primary Liver Cancer

Phase 2 Terminated

3 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT02821533 2017-08-22

Chemoembolization for Hepatocellular Carcinoma

Phase 2 Terminated

24 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT00085410 2017-07-02

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Phase 2 Terminated

20 enrolled 13 charts

Gastrointestinal

Bile Duct Neoplasms, Gallbladder Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular

NCT00787787 2017-06-01

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer

Phase 2 Terminated

41 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

Clinical Trials

LIDA-BII

Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib

Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers

A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

Nivolumab Combined With BMS-986253 in HCC Patients

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

LOST-B

18F-DCFPyL PET/CT in Hepatocellular Carcinoma

Study of Pembrolizumab and Radiotherapy in Liver Cancer

STARBURST

ABE-LIVER

Study of INCB086550 in Select Solid Tumors

ADVANCE HCC

ABT-888 and Temozolomide for Liver Cancer

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

TATE

A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC

Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy

Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)

Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects

Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma

OBT for HCC

TRACE

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma

Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma

Perioperative Therapy for Hepatocellular Carcinoma

ReDos HCC

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma

Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype

Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging

A Phase II Study of Weekly Genexol-PM in Patients With Hepatocelluar Carcinoma After Failure of Sorafenib

LEE001

Pravastatin Intervention to Delay Hepatocellular Carcinoma Recurrence

Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)

A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC

Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma

Gem-ox

Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery

Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer

11C-acetate for Treatment Response After Radiotherapy for HCC

Antineoplaston Therapy in Treating Patients With Primary Liver Cancer

Chemoembolization for Hepatocellular Carcinoma

Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer